Investors Alert: Legal Action Against Hims & Hers Health, Inc. Following Serious Allegations

Pomerantz LLP has recently announced a class action lawsuit targeting Hims & Hers Health, Inc. (NYSE: HIMS), a company known for its telehealth and wellness products. This legal action follows alarming allegations regarding the company’s business practices. Investors who have suffered financial losses are encouraged to take immediate action regarding their claims.

Background of the Class Action

The lawsuit emphasizes that Hims & Hers Health, along with certain executives and board members, may have engaged in deceptive practices and securities fraud. Affected investors must respond soon, as there are approaching deadlines to file claims. Individuals are advised to contact Danielle Peyton at Pomerantz LLP, providing necessary personal information alongside their claim details.

Timeline of Events

On April 29, 2025, Hims & Hers announced a partnership with Novo Nordisk, a collaboration that was meant to boost its product offerings by including the well-known FDA-approved medication Wegovy®. However, circumstances took a dramatic turn when Novo Nordisk publicly severed ties with Hims & Hers on June 23, 2025. The termination stemmed from claims that Hims & Hers was promoting and selling questionable versions of Wegovy®, potentially jeopardizing patient safety.

Novo Nordisk's official statement accused Hims & Hers of failing to comply with legal standards surrounding the marketing of compounded drugs. The company stated that the pharmaceutical ingredients in the products sold by Hims & Hers were sourced from foreign suppliers and had neither received FDA approval nor met safety regulations. These serious accusations have raised substantial concerns among investors about the company's integrity and operational practices.

Impact on Investors

Following the announcement of the terminated partnership, Hims & Hers suffered a significant drop in its stock value, plummeting by $22.24 per share, which translates to a staggering 34.63% decline, finishing at $41.98 per share. Such a sharp downturn raises important questions regarding the company’s practices and the transparency of its dealings with consumers and investors alike.

Next Steps for Investors

Investors who acquired shares during the alleged class period are urged to consider joining the lawsuit to recover potential losses. To take action, interested parties may contact Pomerantz LLP through the provided email address or phone number. Queries via email should include relevant contact details, including mailing addresses and the number of shares purchased.

Pomerantz LLP is widely respected for its expertise in securities class action litigation, boasting a long history of fighting for the rights of wronged investors. With offices located in key cities worldwide, the firm continues to pursue justice for victims of corporate misconduct. They carry a legacy established more than 85 years ago by the pioneering legal mind, Abraham L. Pomerantz, known for his advocacy in securing rights and awards for defrauded investors.

Conclusion

As the legal battle unfolds, stakeholders are advised to remain vigilant and informed about the developments surrounding Hims & Hers Health, Inc. and the implications of these allegations on their investments. The impending deadlines underscore the urgency for affected investors to act quickly in order to assert their rights and recover their losses through collective legal efforts.